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4Abstract 
Background Major depressive disorder (MDD) has a high personal and socio-economic 
burden and more than 60% of patients fail to achieve remission with the first antidepressant. 
The biological mechanisms behind antidepressant response are only partially known but 
genetic factors play a relevant role. A combined predictor across genetic variants may be 
useful to investigate this complex trait. 
Methods Polygenic risk scores (PRS) were used to estimate multi-allelic contribution to: 1) 
antidepressant efficacy; 2) its overlap with MDD and schizophrenia. We constructed PRS and 
tested whether these predicted symptom improvement or remission from the GENDEP study 
(n=736) to the STAR*D study (n=1409) and vice-versa, including the whole sample or only 
patients treated with escitalopram or citalopram. Using summary statistics from Psychiatric 
Genomics Consortium for MDD and schizophrenia, we tested whether PRS from these 
disorders predicted symptom improvement in GENDEP, STAR*D, and five further studies 
(n=3756).  
Results: No significant prediction of antidepressant efficacy was obtained from PRS in 
GENDEP/STAR*D but this analysis might have been underpowered. There was no evidence 
of overlap in the genetics of antidepressant response with either MDD or schizophrenia, 
either in individual studies or a meta-analysis. Stratifying by antidepressant did not alter the 
results.  
Discussion: We identified no significant predictive effect using PRS between 
pharmacogenetic studies. The genetic liability to MDD or schizophrenia did not predict 
response to antidepressants, suggesting differences between the genetic component of 
depression and treatment response. Larger or more homogeneous studies will be necessary to 
obtain a polygenic predictor of antidepressant response.
Keywords: antidepressant; pharmacogenomics; polygenic risk scores; major depressive 
disorder; schizophrenia
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Major depressive disorder (MDD) is a common mental disorder characterized by sadness, 
anhedonia, guilt, feelings of low self-worth, poor concentration, disturbed appetite and sleep 
and suicidal thoughts (World Health Organization, 1993; American Psychiatric Association, 
2013). Its heavy socio-economic and individual burden makes it a global concern: lifetime 
prevalence of MDD ranges from 10% to 15% and MDD is one of the top ten causes of years 
lived with disability (YLDs) worldwide (The WHO World Mental Health Survey 
Consortium, 2004; Global Burden of Disease Study 2013 Collaborators, 2015). 
Antidepressant drugs are the first-line treatment for MDD, with more than 30 antidepressant 
drugs available (Fabbri et al., 2016). Responses vary widely across individuals: one third of 
patients show complete remission after the first drug prescribed, one third improves after a 
change of treatment or augmentation, and one third fail to respond after two different 
antidepressants prescribed (Trivedi et al., 2006; Souery et al., 2011). For each patient, the 
most effective treatment can only be identified by trial and error - a lengthy process which 
delays recovery and leads to poorer clinical outcomes (Steimer et al., 2001). The ability to 
identify the most effective drugs for each patient or to predict treatment resistance would be a 
turning point in MDD treatment, enabling personalized prescribing. However, no predictor of 
antidepressant response is currently available; clinical characteristics are weak predictors of 
improvement in depressive symptoms, and no established biomarkers or genetic signatures 
exist for antidepressant response.
Genome-wide association studies (GWAS) to identify single nucleotide polymorphisms 
(SNPs) associated with antidepressant response have provided tentative hints, but most 
associations have been inconclusive and are unreplicated (Myung et al., 2015; Sasayama et 
al., 2013; Biernacka et al., 2015; GENDEP Investigators, MARS Investigators and STAR*D 
Investigators, 2013; Uher et al., 2010; Trivedi et al., 2006; Ising et al., 2009). These 
disappointing findings may be ascribed to several features of pharmacogenetic studies: 
limited sample size, heterogeneity between studies in design, drug, and assessment of 
outcome. Given the challenges of accruing sufficiently strong evidence to confirm association 
of a single SNP with antidepressant response, an alternative approach is to construct a single 
summary genetic variable representing genome-wide information which can be used for 
prediction. 
Polygenic risk scores (PRS) capture in a single variable the additive effect of SNP alleles 
across the genome (Dudbridge, 2013). In contrast to GWAS analysis, where a single SNP 
must reach stringent significance levels, PRS are constructed from multiple SNPs with lower 
evidence of association, with the assumption that genetic markers that do not meet the 
genome-wide significance threshold might have good predictive power when they are 
considered collectively.
In this study we test whether polygenic risk scores can provide prediction of response to anti-
depressants, building PRS directly from clinical trials of antidepressant response (STAR*D, 
GENDEP) (Garriock et al., 2010; Uher et al., 2010), and secondly testing the hypothesis of 
whether genetic liability to the psychiatric disorders of MDD and schizophrenia contributes 
6to variation in antidepressant response. Indeed an overlap between the genetics of MDD and 
antidepressant response has been hypothesized, but MDD also shares susceptibility genetic 
factors with schizophrenia (Cross-Disorder Group of the Psychiatric Genomics Consortium, 
2013), suggesting a possible overlap between the genetics of schizophrenia and 
antidepressant response. We analyse two large pharmacogenetic trials (GENDEP, STAR*D) 
and expand our study to other studies of antidepressant response, giving a substantial sample 
size in which to develop and test predictors of treatment response.
Materials and Methods 
Pharmacogenetic studies 
Seven pharmacogenetic studies were included, all similar in their fundamental features: (1) 
participants were treatment-seeking individuals diagnosed with MDD based on DSM-
IV/ICD-10 criteria (World Health Organization, 1993; American Psychiatric Association, 
2013), with other psychiatric diagnoses excluded (schizophrenia spectrum disorders, bipolar 
disorders, current alcohol or drug dependence). For each study participant, prospective data 
on outcome of antidepressant treatment were recorded according to standard and comparable 
scales. Missing end-point measurements were imputed using the best unbiased estimate from 
a mixed-effect linear regression model, with fixed linear and quadratic effects of time and 
random effects of individual and centre of recruitment (for multi-centric studies) according to 
previous studies (Tansey et al., 2012; Uher et al., 2010). Patients were included in the 
analyses only if baseline assessment and at least one post-baseline assessment were available. 
The GENDEP and STAR*D studies formed our primary studies for discovery and testing 
variants specific to antidepressant response. For testing the hypothesis that genetic liability 
for MDD and schizophrenia predicts antidepressant response, we included four further trials 
from the NEWMEDS consortium (GENPOD, GODS, GSK, Pfizer) (Tansey et al., 2012) and 
a newly genotyped naturalistic study from the University of Muenster (Baune et al., 2008, 
2010). All studies were approved by local ethics boards of participating centres, and all 
participants provided written informed consent after the study procedures were explained and 
prior to sample collection. Detailed information for each sample are given in Table 1 and 
Supplementary Methods.
Outcome measures 
Two phenotypes were investigated at the end-point of each study, a continuous measure of 
improvement, calculated as the percentage change in symptom score, and symptom remission 
(Table 1). Percentage change was preferred to absolute change because it is less correlated 
with initial severity, relatively independent of the scale, and closely reflects clinician’s 
impression of improvement (Uher et al., 2009; Lane, 2008; Mallinckrodt, Clark and David, 
2001). Remission was defined as a score below a consensus cut-off that corresponds to 
absence of depression for each scale (Hamilton, 1967; Montgomery and Asberg, 1979; Beck 
et al., 1961). For GENDEP, remission was defined using HAMD-17, since there was stronger 
consensus about the threshold to identify remission on this scale compared to MADRS (Uher 
7et al., 2008). Remission has lower power to detect an effect than a continuous measure 
(Streiner, 2002) but it may be associated with MDD prognosis (Gaynes et al., 2009). 
Psychiatric Genomics Consortium summary statistics
Genome-wide summary statistics for large meta-analysis from the Psychiatric Genomics 
Consortium (PGC) were used to construct PRS for MDD and schizophrenia for each 
participant in the pharmacogenomic studies.  Summary statistics for schizophrenia were 
downloaded from pgc.unc.edu (36,989 schizophrenia cases, 113,075 controls) (Ripke et al., 
2014). MDD summary statistics were from the latest PGC MDD meta-analysis comprising 
51,865 MDD cases and 112,200 controls (unpublished data).
Statistical analysis 
Individual-level genotypes were available for all pharmacogenetic studies. GENDEP and 
STAR*D were imputed using genotype data from genome-wide and exome arrays capturing 
both common and rare variation (Table 1; Supplementary Methods). The Muenster study was 
imputed from Infinium PsychArray-24, and phenotype and genotype data from studies in the 
NEWMEDS consortium (GENPOD, Pfizer,GSK, GODS) were used as previously reported 
(Tansey et al., 2012). All these studies were imputed using Minimac3 and the Haplotype 
Reference Consortium (HRC version 1) as reference panel. In STAR*D and GENDEP, tests 
of SNP association were performed using linear regression (for percentage change in 
symptom score) and logistic regression (remission) using PLINK (Purcell et al., 2007). Each 
model included covariates of ancestry-informative principal components, age, baseline 
severity of depression and ascertainment centre (for multi-centre studies of STAR*D, 
GENDEP and Pfizer).  
GWAS summary data from GENDEP, STAR*D, PGC-SCZ, and PGC-MDD were used as 
discovery studies. A schematic representation of study design is provided in Figure 1. SNPs 
were clumped by linkage disequilibrium (LD) and p-value: SNP with the smallest p-value 
within a 250 Kb window were retained, and all SNPs in LD (r2 > 0.1) with the retained SNP 
were excluded. When PGC-MDD was used as discovery study, markers with allele frequency 
diﬀerence of over 0.15 between discovery and test data sets were excluded to ensure 
comparability given the diﬀerent genotyping chips and imputation reference panels used. 
PRS were constructed using the software PRSice v.1.25 (Euesden, Lewis and O’Reilly, 
2015). PRS were calculated as the sum of associated alleles, weighted by eﬀect sizes, for 
SNPs with p-values less than pre-defined threshold PT. Nine p-value thresholds of PT < 
(0.0001, 0.001, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1) were used with all pruned SNPs included in the 
final threshold PT=1. Symptom improvement and remission outcomes were regressed on 
polygenic scores, adjusting for the covariates as used in the GWAS analyses, and compared 
to a model including only covariates. The proportion of phenotypic variance explained by 
PRS was assessed by R2 (for improvement) or Nagelkerke’s R2 (for remission). To decrease 
pharmacological heterogeneity across samples and to increase power, analyses were repeated 
stratifying by antidepressant, including only studies using escitalopram and citalopram 
(STAR*D, GSK, 417 GENDEP participants, 242 GENPOD participants and 121 Muenster 
participants).
8Prediction of improvement from MDD and schizophrenia was implemented separately in 
each pharmacogenetic study, then a fixed effects meta-analysis was performed to combine 
results across studies at each PT.  
A Bonferroni correction was applied to account for multiple testing. We estimated p=0.01 as 
an approximate correction for correlation between PRS at 9 PT values, and then corrected 
further for four independent hypotheses, giving a required significance level of p=0.0025.  
Power calculation 
Power calculations for the polygenic analysis were performed using the R package 
AVENGEME (Palla and Dudbridge, 2015), at each PT. Models assumed SNP heritability of 
0.21 for MDD (Cross-Disorder Group of the Psychiatric Genomics Consortium et al., 2013), 
0.42 for response to antidepressants (Tansey et al., 2013) and 0.33 for schizophrenia (Ripke 
et al., 2013a). Lifetime prevalences used were 16.2% for MDD (Kessler et al., 2003), and 
0.87% for schizophrenia (Perälä et al., 2007). The models used for power calculation 
assumed that the markers are independent and 5% of SNPs have an eﬀect in the training 
phenotype. For cross-trait polygenic analysis (MDD, schizophrenia and antidepressant 
response), two hypothetical scenarios were tested, comparing change in prediction accuracy 
when covariance between genetic eﬀects in the training and target samples were 25% or 
50%.
With GENDEP or STAR*D as discovery sample, the power to detect the genetic contribution 
of response to antidepressants was limited (12% for improvement, 8% for remission).  Using 
PGC MDD and PGC SCZ as discovery had higher power.  Assuming a covariance of 25% 
between SCZ and improvement in depression symptoms gave >90% power in the combined 
pharmacogenetic samples. A covariance of 50% between MDD and improvement in 
depression symptoms had 90% power to detect an effect in the combined pharmacogenetic 
sample, but only power of 37% with 25% covariance.    
9Results 
Firstly, we tested whether PRS predict improvement and remission in depression symptoms 
after twelve weeks of antidepressant treatment, using GENDEP and STAR*D. Each study 
was used as discovery and then as target study, testing the PRS constructed from STAR*D 
GWAS results in GENDEP, and vice-versa.  No significant prediction of treatment response 
was attained for improvement or for remission in the whole sample (Supplementary Figure 1) 
or restricting the analysis to citalopram/escitalopram (Supplementary Figure 2) treated 
patients (Table 2). The lowest p-value of p=0.023, using the GENDEP remission GWAS to 
predict remission in STAR*D, did not reach the required Bonferroni correction of 0.0025.  
Secondly, we investigated whether genetic liability to MDD or schizophrenia predicted 
improvement in depressive symptoms, using meta-analyses from the Psychiatric Genomics 
Consortium (PGC) as discovery samples. Seven pharmacogenetic studies (including 
GENDEP and STAR*D) were used as independent target samples (3746 participants). Meta-
analysis across studies (whole sample or citalopram/escitalopram treated patients) showed no 
predictive ability of genetic liability for MDD or for schizophrenia (Figure 2), with the most 
significant result being for schizophrenia PRS at PT<0.0001 (p=0.077). Across all PT, PRS for 
MDD showed p-values > 0.1 for the prediction of symptom improvement and regression 
coefficients explained less than 3% of the variance in symptom improvement.  Results by-
study at all PT values are given in Supplementary Tables 1-2.
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Discussion 
In this study, we assessed whether the outcomes of antidepressant treatment may be predicted 
by PRS for (a) improvement and remission from an independent sample, (b) genetic liability 
to MDD, and (c) genetic liability to schizophrenia.  Using each of the two largest available 
pharmacogenetic samples on antidepressant response (GENDEP and STAR*D) as baseline 
studies failed to predict antidepressant response in the other study. A previous study 
(GENDEP Investigators, MARS Investigators and STAR*D Investigators, 2013) found a 
small predicting ability of a PRS calculated in a meta-analysis of GENDEP-MARS studies in 
STAR*D, accounting for about 1.2% of the variance in outcomes in STAR*D.  The present 
study was performed using individual datasets as discovery samples but increasing the 
number of genetic variants from ~ 1.2 million to ~ 7 million.  PRS built from well-powered 
PGC studies for MDD and schizophrenia did not predict symptom improvement, either in 
individual pharmacogenetic studies, or in a meta-analysis. A previous analysis of PRS for 
bipolar disorder did not predict antidepressant response in STAR*D and the NEWMEDS 
studies, so this analysis was not repeated here (Tansey et al., 2014). 
This study represents the largest investigation of the PRS for antidepressant response to date, 
including the majority of currently available pharmacogenetic data on antidepressant 
response in MDD (3,746 participants from 7 studies). Both PGC discovery studies were well 
powered. The PGC schizophrenia study identified a genetic component accounting for 
approximately 7% of the liability to schizophrenia. MDD shares susceptibility genetic factors 
with schizophrenia (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013), 
suggesting a possible overlap between the genetics of schizophrenia and antidepressant 
response. The unpublished PGC MDD meta-analysis has a substantially increased sample 
size from the previous study (Ripke et al., 2013b) as well as from the recent MDD GWAS 
from 23andme (Hyde et al., 2016). MDD PRS comparable to the ones we calculated could 
not be constructed from the 23andme study since only SNPs with p<10-5 are publicly 
available.
Despite the extensive resources analysed, the power to detect predictions across study using 
PRS remained low for antidepressant response, although the power was adequate when we 
investigated common genetic liability with MDD and schizophrenia.  The modest 
pharmacogenetic study sample sizes also precluded other whole-genome-approaches to 
estimate genetic correlation using GCTA or LD score regression (Yang et al., 2011; Bulik-
Sullivan et al., 2015). A sample size ten-times larger would be required to achieve 80% for 
polygenic prediction between studies of antidepressant response.  National registers and 
electronic medical records of large health care organisations could be used to achieve a study 
of this magnitude, but requires substantial resources for selection of appropriate subjects, 
phenotyping, DNA collection, genotyping and analysis.  The power to detect common 
liability with psychiatric disorders was higher, but required the assumption of high genetic 
correlation. 
Other limitations of the study arise from the differences in pharmacogenetic studies in 
characteristics of ascertainment, baseline severity, treatment, assessment of outcome and 
length of follow-up.  We chose to focus on two largest studies (GENDEP, STAR*D) in test 
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PRS for antidepressant response, to avoid adding multiple smaller studies where noise would 
outweigh signal.  In the higher powered analysis assessing genetic component of MDD and 
schizophrenia, we included all available pharmacogenetic studies. Although there were 
substantial diﬀerences in the design of the studies, inclusion criteria were relatively similar 
and it was possible to establish comparable outcome measures. Ethnicity is also a possible 
cause of stratification in GWAS despite correction using ancestry-informative principal 
components. 
We performed a single sub-analysis restricting to participants treated by citalopram or 
escitalopram, since escitalopram is the active isomer of citalopram (N=2308 participants) 
(Svensson and Mansfield, 2004). These analyses also failed to predict improvement of anti-
depressant symptoms or remission. Many further sub-hypotheses could be tested, for 
example, stratifying by sex, symptom dimensions, age, or severity.  Recognising the need to 
balance a larger effect size in one subgroup against the smaller sample size and increased 
correction for multiple testing, we focussed on the key hypotheses (Traylor, Markus and 
Lewis, 2015).
The identification of individual genetic associations with antidepressant treatment response 
has been challenging, with no genome-wide studies identifying replicated signals for 
association (Uher et al., 2010; Garriock et al., 2010; Ising et al., 2009). Since no major, 
single locus variants play a major role in treatment response, building polygenic predictors, 
which capture modest effects at multiple SNPs, may be a feasible alternative.  STAR*D, 
GENDEP and other NEWMEDS studies show a strong polygenic component to the genetic 
architecture of response to antidepressants, with common genetic variation estimated to 
explain 42% of individual differences (SE = 0.180, p = 0.009) (Tansey et al., 2013). With the 
decreasing costs of genotyping, and increasing access to such data, a PRS could form a 
powerful predictor response, and be of clinical value, as already seen in predicting disease 
risk (Chhibber et al., 2014; Chatterjee, Shi and García-Closas, 2016).  Other strategies, such 
as machine learning application to clinical and genetic variables in STAR*D and NEWMEDs 
studies showed some prediction based on both genetic and clinical characteristics, which was 
antidepressant specific (Iniesta et al., 2016). 
We selected here two reasonable polygenic hypotheses that (1) the genetic component of 
antidepressant response from a single study would transfer across studies, and (2) that genetic 
liability for psychiatric disorders would predict response to antidepressants.  Neither of 
hypotheses could be confirmed in the currently available datasets and true polygenic 
component for antidepressant response would require much larger cohorts.  Recent successes 
in uncovering the genetic component of psychiatric disorders are encouraging, but progress in 
uncovering the genetic component to treatment response remains slower.  Expanded cohorts 
will be necessary to uncover the genetic architecture of antidepressant response, an essential 
step if precision medicine in depression is to become attainable.  
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Figure 1:  Study design, capturing (1) prediction of improvement and remission using large 
antidepressant response trials as discovery studies, and (2) prediction from psychiatric disorder 
PRS, into all antidepressant studies. Arrows indicate PRS from discovery to test data sets.  
PGC=Psychiatric Genomics Consortium. 
Figure 2:  Meta-analysis of PRS effect sizes (β) in seven pharmacogenetic studies for (1) MDD and 
(2) schizophrenia PRS.  Labels show p-values for meta-analyses at each p threshold.
1. MDD
2. Schizophrenia
Table 1 Pharmacogenetic study characteristics. MADRS; Montgomery-Åsberg Depression Rating Scale. QIDS-C16; Quick Inventory of Depressive Symptomatology-Clinician 
Rated. BDI; Beck Depression Inventory. HAMD-17; Hamilton Rating Scale for Depression (17 items). HAMD-21; Hamilton Rating Scale for Depression (21 items). SSRIs; 
selective serotonin reuptake inhibitors. SNRIs; serotonin and noradrenaline reuptake inhibitors. 
STAR*D GENDEP GENPOD Pfizer GSK GODS Muenster
Sample characteristics
Study design Trial Trial Trial Trial Trial Trial Naturalistic
N 1409 736 473 307 130 70 621
Scale for outcome assessment QIDS-C16 MADRS BDI HAMD-17 HAMD-17 MADRS HAMD-21
Time of end point assessment 12 weeks 12 weeks 12 weeks 12 weeks 12 weeks 12 weeks 6 weeks
Criteria for remission QIDS-C16 ≤ 5 HAMD-17 ≤ 7 BDI < 10 HAMD-17 ≤ 7 HAMD-17 ≤ 7 MADRS ≤ 8 HAMD-21 ≤ 7
Treatment citalopram
escitalopram     
nortriptyline
citalopram 
reboxetine
sertraline    
fluoxetine   
paroxetine
escitalopram paroxetine
SSRIs, SNRIs, 
others
Genotyping platform Affymetrix   500K, 
Illumina Infinium 
Exome-24 v1.0
Illumina Human610,  
Infinium Exome-24 v1.0 
Illumina 660W Illumina 660W Illumina 660W Illumina 660W  Infinium 
PsychArray-24
Imputation panel Haplotype Reference 
Consortium
Haplotype Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Haplotype 
Reference 
Consortium
Clinical characteristics
% Female 59.9 62 69.2 67.2 54.5 53.4 43.1
Age at onset 27.3 (SD 14.2) 32.0 (SD 10.6) 39.4 (SD 12.5) 43.3 (SD 13.1) 36.4 (SD 11.9) 37.1 (SD 10.3) 39.0 (SD 15.0)
MDD severity
Moderate to Severe Moderate to Severe
Moderate to 
Severe
Moderate to Severe
Moderate to 
Severe
Severe Mild to Severe
Baseline measure
HAMD-17 HAMD-17 BDI HAMD-17 HAMD-17 MADRS HAMD-21
Score 22.4 (SD 4.9) 21.9 (SD 5.2) 33.4 (SD 9.7) 23.5 (SD 3.4) 23.0 (SD 3.1) 31.8 (SD 4.7) 22.3 (SD 7.3)
Achieved remission 602 (42.7%) 322 (44%) 171 (36%) 100 (32%) 56 (43%) 17 (24%) 279 (45%)

Table 2:  Prediction of improvement in depression symptoms and remission after 12 weeks of 
antidepressant treatment. Results are shown for the PT threshold attaining the lowest p-value. R2; 
Proportion of variance explained.
Discovery 
sample
Target 
sample
Phenotype PT
No. of 
SNPs
R2 P-value
Whole sample
Improvement 0.001 1422 0.00079 0.280
GENDEP STAR*D
Remission 0.0001 934 0.00044 0.024
Improvement 0.05 39471 0.00173 0.237
STAR*D GENDEP
Remission 0.5 214280 0.00212 0.234
Analyses including only citalopram/escitalopram treated 
subjects
Improvement 0.001 1429 0.00056 0.361
GENDEP STAR*D
Remission 0.001 827 0.00199 0.130
Improvement 0.05 39471 0.00214 0.313
STAR*D GENDEP
Remission 0.5 214280 0.00335 0.255
